Literature DB >> 25987170

Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.

Maurizio Scarpa1, Cinzia Maria Bellettato2, Christina Lampe3, David J Begley4.   

Abstract

Pharmacological research has always focused on developing new therapeutic strategies capable of modifying a disease's natural history and improving patients' quality of life. Despite recent advances within the fields of medicine and biology, some diseases still represent a major challenge for successful therapy. Neuronopathic lysosomal storage disorders, in particular, have high rates of morbidity and mortality and a devastating socio-economic effect. Many of the available therapies, such as enzyme replacement therapy, can reverse the natural history of the disease in peripheral organs but, unfortunately, are still unable to reach the central nervous system effectively because they cannot cross the blood-brain barrier that surrounds and protects the brain. Moreover, many lysosomal storage disorders are characterized by a number of blood-brain barrier dysfunctions, which may further contribute to disease neuropathology and accelerate neuronal cell death. These issues, and their context in the development of new therapeutic strategies, will be discussed in detail in this chapter.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  blood–brain barrier; central nervous system; drug delivery; lysosomal storage disorders; neurodegeneration

Mesh:

Substances:

Year:  2015        PMID: 25987170     DOI: 10.1016/j.beem.2014.12.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  6 in total

Review 1.  Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.

Authors:  Raluca Ioana Teleanu; Manuela Daniela Preda; Adelina-Gabriela Niculescu; Oana Vladâcenco; Crina Ioana Radu; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Pharmaceutics       Date:  2022-05-04       Impact factor: 6.525

Review 2.  Disease models for the development of therapies for lysosomal storage diseases.

Authors:  Miao Xu; Omid Motabar; Marc Ferrer; Juan J Marugan; Wei Zheng; Elizabeth A Ottinger
Journal:  Ann N Y Acad Sci       Date:  2016-05-04       Impact factor: 5.691

3.  Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.

Authors:  Christopher J Folts; Nicole Scott-Hewitt; Christoph Pröschel; Margot Mayer-Pröschel; Mark Noble
Journal:  PLoS Biol       Date:  2016-12-15       Impact factor: 8.029

4.  Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.

Authors:  Annie Arguello; Cathal S Mahon; Meredith E K Calvert; Darren Chan; Jason C Dugas; Michelle E Pizzo; Elliot R Thomsen; Roni Chau; Lorna A Damo; Joseph Duque; Meng Fang; Tina Giese; Do Jin Kim; Nicholas Liang; Hoang N Nguyen; Hilda Solanoy; Buyankhishig Tsogtbaatar; Julie C Ullman; Junhua Wang; Mark S Dennis; Dolores Diaz; Kannan Gunasekaran; Kirk R Henne; Joseph W Lewcock; Pascal E Sanchez; Matthew D Troyer; Jeffrey M Harris; Kimberly Scearce-Levie; Lu Shan; Ryan J Watts; Robert G Thorne; Anastasia G Henry; Mihalis S Kariolis
Journal:  J Exp Med       Date:  2022-02-28       Impact factor: 14.307

Review 5.  Possible strategies to cross the blood-brain barrier.

Authors:  Cinzia M Bellettato; Maurizio Scarpa
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

Review 6.  The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives.

Authors:  Noemi Veraldi; Nawel Zouggari; Ariane de Agostini
Journal:  Molecules       Date:  2020-01-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.